In subgroup analyses, the benefits of DPP‐4is on the progression of OCAD in patients with T2DM receiving insulin therapy were consistent across various prespecified subgroups, classified according to the baseline HbA1c, prior comorbidities, and the presence of an OCAD at baseline (Figure 2). Here, INS is linked to type 2 diabetes mellitus.